An Introduction of EVIDEM Framework and Its Application in Healthcare Decision Making

Ze-qi DAI; Si-min XU; Xue WU; Lu-lu JIA; Jin-song GENG; Hui ZHAO; Xing LIAO

doi:10.13422/j.cnki.syfjx.20220154

您当前的位置：

首页 >

文章列表页 >

An Introduction of EVIDEM Framework and Its Application in Healthcare Decision Making

更新时间：2022-01-13

- An Introduction of EVIDEM Framework and Its Application in Healthcare Decision Making
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 28, Issue 4, Pages: 212-218(2022)
- 作者机构：
  
  1.中国中医科学院中医临床基础医学研究所循证医学基础研究室，北京 100700
  2.中国中医药循证医学中心，北京 100700
  3.首都医科大学附属北京儿童医院，北京 100045
  4.南通大学医学院，江苏南通 226001
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20220154
  CLC： R24;R4;R286
- Received：27 December 2021，
  
  Published Online：31 December 2021，
  
  Published：20 February 2022
- 稿件说明：
移动端阅览
戴泽琦,徐思敏,吴雪等.EVIDEM框架介绍及其在卫生决策中的应用[J].中国实验方剂学杂志,2022,28(04):212-218.

DAI Ze-qi,XU Si-min,WU Xue,et al.An Introduction of EVIDEM Framework and Its Application in Healthcare Decision Making[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(04):212-218.
戴泽琦,徐思敏,吴雪等.EVIDEM框架介绍及其在卫生决策中的应用[J].中国实验方剂学杂志,2022,28(04):212-218. DOI： 10.13422/j.cnki.syfjx.20220154.

DAI Ze-qi,XU Si-min,WU Xue,et al.An Introduction of EVIDEM Framework and Its Application in Healthcare Decision Making[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(04):212-218. DOI： 10.13422/j.cnki.syfjx.20220154.

摘要

证据与价值对决策的影响（EVIDEM）框架由EVIDEM协作组开发，其内核是多准则决策分析（MCDA）模型与标准化卫生技术评估（HTA）报告结合的产物，旨在评估医疗干预的整体价值，已在真实世界评价环境中得到了测试和实施。历经10多年的发展，EVIDEM框架已更新到第10版，且发布了相关的操作手册，40多个国家加入该协作网，20多个国家开展了相关研究。该框架以患者、群体、可持续性为总体目标构建，将证据与价值相结合，形成了由2个层面，7个维度和20个准则组成的一套较为完整的决策框架体系。2个层面包括规范化的通用准则和情景化准则。规范化的通用准则，即EVIDEM核心模型，为定量评价，由5个维度和13个准则组成。情境化准则，即情境化工具，为定性评价，由2个维度和7个准则组成。EVIDEM框架的具体操作步骤包括选择和构建准则、赋权、整合和评价证据、价值的定量与定性评估、综合价值估计及基于价值估计的排序。EVIDEM框架适用于疾病的诊断、治疗、管理等领域，应用范围包括医疗保险报销、临床实践决策、药品遴选等，可为更加系统、透明、科学的卫生决策提供方法。目前该框架已被引入中医药领域，可为中成药的临床综合评价提供一个科学易行的评估工具及方法体系。

Abstract

Evidence and value：impact on DEcisionMaking （EVIDEM） framework was developed by EVIDEM collaboration. Its core is the combination of multiple criteria decision analysis （MCDA） model and standardized health technology assessment （HTA） report， which aims to evaluate the overall value of medical interventions. It has been tested and implemented in the real-world evaluation environments. After more than 10 years of development， EVIDEM framework has been updated to version 10， and the relevant operation manuals have been published. More than 40 countries have joined the collaboration and more than 20 countries have carried out relevant studies. The framework is constructed with patients， population and sustainability as the overall goals， combing the evidence and value， forming a relatively complete decision-making framework system composed of 2 levels， 7 dimensions and 20 criteria. The two levels include normative universal criteria and contextual criteria. The normative universal criteria， namely EVIDEM core model， is the quantitative evaluation， consisting of 5 dimensions and 13 criteria. Contextual criteria， namely contextual tools， are qualitative evaluation， consisting of 2 dimensions and 7 criteria. The specific operation steps of EVIDEM framework include selecting and constructing criteria， assigning weights， integrating and evaluating evidence， quantitative and qualitative evaluation of value， comprehensive value estimation and ranking based on value estimation. EVIDEM framework is applicable to disease diagnosis， treatment， management and other fields. Its application scope includes medical insurance reimbursement， clinical practice decision-making， drug selection and so on， which can provide a method for more systematic， transparent and scientific healthcare decision-making. At present， the framework has been introduced into the field of traditional Chinese medicine and can provide a scientific and feasible evaluation tool and methodology system for the clinical comprehensive evaluation of Chinese patent medicine.

关键词

Keywords

references

鲍海妮，余小兰，耿劲松，等 . 医药卫生领域多准则决策分析的方法学［J］. 中国卫生资源， 2020 ， 23 （ 4 ）： 337 - 341 .

GOETGHEBEUR M M ， WAGNER M ， KHOURY H ， et al . Evidence and value：impact on DEcisionMaking-the EVIDEM framework and potential applications ［J］. BMC Health Serv Res ， 2008 ， 8 ： 270 .

GOETGHEBEUR M M ， CELLIER M S . Can reflective multicriteria be the new paradigm for healthcare decision-making？ The EVIDEM journey ［J］. Cost Eff Resour Alloc ， 2018 ， 16 （ Suppl 1 ）： 54 .

廖星，郭武栋，曹庄，等 . 应用卫生技术评估开展中成药临床综合评价［J］. 中国中药杂志， 2020 ， 45 （ 16 ）： 3749 - 3758 .

MARSH K ， GOETGHEBEUR M ， THOKALA P ， et al . Multi-criteria decision analysis to support healthcare decisions ［M］. Cham ： Springer International Publishing AG ， 2017 .

GOETGHEBEUR M M ， WAGNER M ， KHOURY H ， et al . Bridging health technology assessment （HTA） and efficient health care decision making with multicriteria decision analysis （MCDA）：applying the EVIDEM framework to medicines appraisal ［J］. Med Decis Making ， 2012 ， 32 （ 2 ）： 376 - 388 .

GOETGHEBEUR M M ， WAGNER M ， KHOURY H ， et al . Combining multicriteria decision analysis，ethics and health technology assessment：applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients ［J］. Cost Eff Resour Alloc ， 2010 ， 8 ： 4 .

TONY M ， WAGNER M ， KHOURY H ， et al . Bridging health technology assessment （HTA） with multicriteria decision analyses （MCDA）：field testing of the EVIDEM framework for coverage decisions by a public payer in Canada ［J］. BMC Health Serv Res ， 2011 ， 11 ： 329 .

耿劲松，鲍海妮，余小兰，等 . “证据与价值对决策的影响”框架在知证决策中应用的方法学［J］. 中国卫生资源， 2020 ， 23 （ 4 ）： 342 - 347 .

MIOT J ， WAGNER M ， KHOURY H ， et al . Field testing of a multicriteria decision analysis （MCDA） framework for coverage of a screening test for cervical cancer in South Africa ［J］. Cost Eff Resour Alloc ， 2012 ， 10 （ 1 ）： 2 .

WAHLSTER P ， GOETGHEBEUR M ， SCHALLER S ， et al . Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study ［J］. Health Res Policy Syst ， 2015 ， 13 ： 24 .

GARAU M ， HAMPSON G ， DEVLIN N ， et al . Applying a multicriteria decision analysis （MCDA） approach to elicit stakeholders' preferences in Italy：The case of obinutuzumab for rituximab-refractory indolent non-hodgkin lymphoma （iNHL）［J］. Pharmacoecon Open ， 2018 ， 2 （ 2 ）： 153 - 163 .

耿劲松，陈晓炜，余小兰，等 . 基于EVIDEM的新技术医保报销循证决策框架探析［J］. 中国卫生政策研究， 2018 ， 11 （ 4 ）： 50 - 54 .

ÁLVAREZ-ROMÁN M T ， CUERVO-ARANGO I ， PÉREZ-SANTAMARINA R ， et al . Determining the value contribution of emicizumab （Hemlibra ® ） for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis ［J］. Glob Reg Health Technol Assess ， 2019 ， doi： 10.1177/2284240319880534 http://dx.doi.org/10.1177/2284240319880534 .

WANGER M ， SAMAHA D ， KHOURY H ， et al . Development of a framework based on reflective MCDA to support patient-clinician shared decision-making：the case of the management of gastroenteropancreatic neuroendocrine tumors （GEP-NET） in the United States ［J］. Adv Ther ， 2018 ， 35 （ 1 ）： 81 - 99 .

WAGNER M ， SAMAHA D ， CUERVO J ， et al . Applying reflective multicriteria decision analysis （MCDA） to patient-clinician shared decision-making on the management of gastroenteropancreatic neuroendocrine tumors （GEP-NET） in the spanish context ［J］. Adv Ther ， 2018 ， 35 （ 8 ）： 1215 - 1231 .

WAGNER M ， KHOURY H ， BENNETTS L ， et al . Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer：a multi-country study applying pragmatic MCDA ［J］. BMC Cancer ， 2017 ， 17 （ 1 ）： 272 .

宋子扬，尉耘翠，聂晓璐，等 . 基于卫生技术评估联合多准则决策分析建立我国儿童用药临床综合评价方法［J］. 药物流行病学杂志， 2019 ， 28 （ 10 ）： 681 - 686 .

卫生部，国家中医药管理局，总后勤部卫生部 . 医疗机构药事管理规定［EB/OL］.（ 2011-04-07 ）［ 2021-11-22 ］. http：//fjs.satcm.gov.cn/gongzuodongtai/2018-03-24/2269.html http://fjs.satcm.gov.cn/gongzuodongtai/2018-03-24/2269.html .

薛朝军，任炳楠，郭彩会，等 . 基于EVIDEM理念的医疗机构药品遴选多准则循证决策框架探究［J］. 中国医院药学杂志， 2021 ， 41 （ 3 ）： 303 - 308 .

BAO Y ， GAO B ， MENG M ， et al . Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making：determining the value of five dipeptidyl peptidase 4 （DPP-4） inhibitors ［J］. BMC Health Serv Res ， 2021 ， 21 （ 1 ）： 807 .

WAGNER M ， KHOURY H ， WILLET J ， et al . Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases：analysis of issues and policies，and context-specific adaptation ［J］. Pharmacoeconomics ， 2016 ， 34 （ 3 ）： 285 - 301 .

GOETGHEBEUR M M ， WAGNER M ， NIKODEM M ， et al . Pragmatic multicriteria decision analysis （MCDA） combined with advanced pharmacoepidemiology for benefit-risk assessments of medicines adapted to the real-life constraints of regulators：development and case study ［J］. Ther Innov Regul Sci ， 2016 ， 50 （ 5 ）： 620 - 631 .

CASTRO-JARAMILLO H E ， GOETGHEBEUR M ， MORENO-MATTAR O . Testing multi-criteria decision analysis for more transparent resource-allocation decision making in Colombia ［J］. Int J Technol Assess Health Care ， 2016 ， 32 （ 4 ）： 307 - 314 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction and Interpretation of Clinical Comprehensive Evaluation Index System for Chinese Patent Medicine Based on EVIDEM Framework

Current Situation on Clinical Comprehensive Evaluation of Chinese Patent Medicines in China

Clinical Comprehensive Evaluation of Biantong Capsules and Biantong Tablets in Treatment of Constipation

Feasibility Analysis of EVIDEM Framework in Health Technology Assessment of Traditional Chinese Medicine

Related Author

DAI Zeqi

JING Chengyang

WU Xue

ZHANG Le

LIAO Xing

LI Wenshuang

DAI Zeqi

SUN Qingran

Related Institution

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

The research center of national drug policy & ecosystem，China pharmaceutical university

China Academy of Chinese Medical Sciences

NMPA Key Laboratory for Drug Regulatory Innovation and Evaluation，China Pharmaceutical University

Center for Evidence-based Chinese Medicine， Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰